ATE521608T1 - Glucokinaseaktivatoren - Google Patents

Glucokinaseaktivatoren

Info

Publication number
ATE521608T1
ATE521608T1 AT06826456T AT06826456T ATE521608T1 AT E521608 T1 ATE521608 T1 AT E521608T1 AT 06826456 T AT06826456 T AT 06826456T AT 06826456 T AT06826456 T AT 06826456T AT E521608 T1 ATE521608 T1 AT E521608T1
Authority
AT
Austria
Prior art keywords
glucokinase
glucokinase activators
underactivity
diseases
prevention
Prior art date
Application number
AT06826456T
Other languages
German (de)
English (en)
Inventor
Thomas Daniel Aicher
Wai-Man Lee
Ronald Jay Hinklin
Mark Joseph Chicarelli
Steven Armen Boyd
Kevin Ronald Condroski
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Application granted granted Critical
Publication of ATE521608T1 publication Critical patent/ATE521608T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT06826456T 2005-11-01 2006-10-24 Glucokinaseaktivatoren ATE521608T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73203705P 2005-11-01 2005-11-01
PCT/US2006/041251 WO2007053345A1 (en) 2005-11-01 2006-10-24 Glucokinase activators

Publications (1)

Publication Number Publication Date
ATE521608T1 true ATE521608T1 (de) 2011-09-15

Family

ID=37685330

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06826456T ATE521608T1 (de) 2005-11-01 2006-10-24 Glucokinaseaktivatoren

Country Status (9)

Country Link
US (1) US8933077B2 (https=)
EP (1) EP1948652B1 (https=)
JP (1) JP5137207B2 (https=)
AT (1) ATE521608T1 (https=)
AU (1) AU2006309173B2 (https=)
CA (1) CA2628274A1 (https=)
ES (1) ES2372540T3 (https=)
NZ (1) NZ567858A (https=)
WO (1) WO2007053345A1 (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1785420A1 (en) * 2005-11-14 2007-05-16 4Sc Ag Thiazole analogues and uses thereof
JP2010500300A (ja) 2006-08-08 2010-01-07 サノフィ−アベンティス アリールアミノアリール−アルキル−置換イミダゾリジン−2,4−ジオン、それらの製造法、それらの化合物を含有する薬剤、およびそれらの使用
US8362037B2 (en) * 2007-03-23 2013-01-29 Array Biopharma, Inc. 2-aminopyridine analogs as glucokinase activators
WO2009022179A2 (en) * 2007-08-14 2009-02-19 Astrazeneca Ab Glucokinase activators in the treatment of osteoarthritis
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
AU2008305294B2 (en) * 2007-09-21 2012-11-29 Array Biopharma Inc. Pyridin-2 -yl-amino-1, 2, 4 -thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus
JP5567481B2 (ja) * 2007-10-09 2014-08-06 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング グルコキナーゼアクチベーターとして有用なピリジン誘導体
RU2450001C2 (ru) 2007-12-20 2012-05-10 Эл Джи Лайф Сайенсиз Лтд. Активаторы глюкокиназы и фармацевтические композиции, содержащие их в качестве активного ингредиента
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
WO2010106016A1 (en) * 2009-03-17 2010-09-23 Glaxo Group Limited Pyrimidine derivatives used as itk inhibitors
JP5674211B2 (ja) * 2009-07-10 2015-02-25 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH インダゾリル置換のジヒドロイソオキサゾロピリジンおよびその使用方法
MX2012001729A (es) 2009-08-26 2012-06-13 Sanofi Sa Nuevos hidratos cristalinos de fluoroglicosido heteroaromatico, productos farmaceuticos que comprenden estos compuestos, y su empleo.
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
CA2800498C (en) 2010-03-31 2021-11-16 The Scripps Research Institute Reprogramming cells
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
JPWO2012121314A1 (ja) 2011-03-09 2014-07-17 第一三共株式会社 ジピリジルアミン誘導体
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
HK1210969A1 (en) 2012-01-20 2016-05-13 奥克塞拉有限公司 Substituted heterocyclic compounds for disease treatment
WO2013173672A1 (en) 2012-05-18 2013-11-21 Array Biopharma Inc. Method for the preparation of thiadiazoles
TWI695000B (zh) * 2017-10-29 2020-06-01 中國醫藥大學 用於抑制adam9活性之化合物、其醫藥組合物及其用途
KR102919209B1 (ko) 2018-08-10 2026-01-28 다이아핀 테라퓨틱스, 엘엘씨 트리-펩타이드 그리고 대사, 심장혈관 및 염증성 장애의 치료

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596476B1 (en) * 1989-12-22 2003-07-22 Abbott Laboratories Hepatitis C assay
PL215901B1 (pl) 1999-04-15 2014-02-28 Bristol Myers Squibb Co Cykliczny inhibitor bialkowych kinaz tyrozynowych, jego zastosowanie oraz kompozycja farmaceutyczna zawierajaca taki zwiazek
US7125875B2 (en) * 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
DE60023926T2 (de) * 1999-09-10 2006-07-20 Merck & Co., Inc. Tyrosin kinase inhibitoren
NZ526472A (en) * 2000-12-21 2004-04-30 Vertex Pharma Pyrazole compounds useful as protein kinase inhibitors
GB0226931D0 (en) * 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
EP1598349B1 (en) 2003-02-13 2011-07-27 Msd K.K. Novel 2-pyridinecarboxamide derivatives
EP1734040A4 (en) * 2004-03-23 2007-11-28 Banyu Pharma Co Ltd SUBSTITUTED CHINAZOLINE OR PYRIDOPYRIMIDINE DERIVATIVE

Also Published As

Publication number Publication date
US8933077B2 (en) 2015-01-13
JP5137207B2 (ja) 2013-02-06
AU2006309173A1 (en) 2007-05-10
NZ567858A (en) 2011-08-26
CA2628274A1 (en) 2007-05-10
US20100056530A1 (en) 2010-03-04
EP1948652A1 (en) 2008-07-30
AU2006309173B2 (en) 2011-08-18
JP2009513700A (ja) 2009-04-02
ES2372540T3 (es) 2012-01-23
WO2007053345A1 (en) 2007-05-10
EP1948652B1 (en) 2011-08-24

Similar Documents

Publication Publication Date Title
ATE521608T1 (de) Glucokinaseaktivatoren
SG170775A1 (en) 2 -aminopyridine analogs as glucokinase activators
TW200740804A (en) Glucokinase activators
WO2008118718A3 (en) 2-aminopyridine analogs as glucokinase activators
CR11383A (es) Derivados piridin-2-il-amino-1,2,4 -tiadiazol como activadores glucoquinasa para el tratamiento de la diabetes mellitus
NO20074943L (no) Roflumilast for behandlingen av diabetes mellitus
TW200745037A (en) Organic compounds
ATE435015T1 (de) Substituierte benzazole und ihre verwendung als raf-kinase-hemmer
WO2006091459A3 (en) Compositions and methods for treating vascular permeability
TW200608979A (en) Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
MX2007007409A (es) Derivados de rapamicina y los usos de los mismos en el tratamiento de trastornos neurologicos.
EA201071089A1 (ru) Производные хиназолина как модуляторы raf-киназы и способы их применения
GB0402137D0 (en) Novel compounds
ATE480255T1 (de) Zusammensetzungen und verfahren zur kontrolle, prävention und behandlung von essstörungen
CY1109985T1 (el) Αναστολεις πρωτεασωματος και μεθοδοι χρησης αυτων
TNSN06315A1 (en) Sulfonamide-thiazolpyridine derivatives as glucokinase activators useful the treatment of type 2 diabetes
WO2010029089A3 (en) Combination therapy for the treatment of diabetes and related conditions
NO20092639L (no) 4-fenyl-6-(2,2,2-trifluor-1-fenyletoksy)pynmidinbaserte forbindelser og anvendelser derav
GB0402143D0 (en) Novel compounds
MX2007005590A (es) Compuestos del inhibidor glicogeno fosforilasa y sus composiciones farmaceuticas.
TW200714604A (en) Substituted heterocycles and the uses thereof
ATE552000T1 (de) Verwendung von isothiocyanat-verbindungen zur behandlung von prostata-erkrankungen und hautkrebs
ATE438404T1 (de) Verwendung von k-252a und kinasehemmern zur vorbeugung und behandlung von hmgb1-assoziierten pathologien
ATE534649T1 (de) Imidazothiazole und imidazoxazolderivative als inhibitoren von p38
WO2008033440A3 (en) Treatment of hyperproliferative diseases with anthraquinones

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties